Live tape
Top 8, mentions 7d14,336GOOGL2,871 mentions▲ +0.04NVDA2,215 mentions▲ +0.05AMD1,940 mentions▲ +0.08QQQ1,751 mentions▲ +0.05AAPL1,729 mentions▲ +0.05SPY1,560 mentions▲ +0.06TSLA1,164 mentions▲ +0.06SPCX1,106 mentions▲ +0.05

Equity · Healthcare

IMCR

NASDAQ

Immunocore Holdings (IMCR)

35 USD +2.94% vs prior close
Immunocore Holdings plc price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for IMCR to draw a line in its place.

Track this symbol on TradingView
Market cap
1.8B USD
Revenue, year to Dec 2025
400.0M USD
EPS, diluted, year to Dec 2025
−0.71 USD
52-week range
27.93 USD – 40 USD
Avg volume
167.0K

as of Jul 17, 2026

Have Immunocore Holdings (IMCR) insiders bought or sold shares recently?

IMCR has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 18 February 2026.

Form 4

Have Immunocore Holdings (IMCR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
18 Feb 2026Berman David MHEAD OF R&DSell5,965193K USD
18 Feb 2026GOLL JOHNSVP, FINANCE & CAOSell69823K USD
18 Feb 2026Jallal BahijaCHIEF EXECUTIVE OFFICERSell11,474371K USD
18 Feb 2026St Leger Tina AmberCHIEF HR OFFICERSell1,00032K USD
05 Dec 2025Berman David MHEAD OF R&DSell57223K USD
04 Dec 2025Berman David MHEAD OF R&DSell31,3411.3M USD
28 Nov 2025Berman David MHEAD OF R&DSell5,521221K USD
26 Nov 2025Berman David MHEAD OF R&DSell69,4042.8M USD
25 Nov 2025Berman David MHEAD OF R&DSell18,020721K USD
24 Nov 2025Berman David MHEAD OF R&DSell1004K USD
Sold10 open-market sales144,095$5.63M
10 other filings: grants, exercises, tax withholding and transfers, not trades
Have Immunocore Holdings (IMCR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
17 Feb 2026Berman David MHEAD OF R&DOption exercise11,824
17 Feb 2026GOLL JOHNSVP, FINANCE & CAOOption exercise1,351
17 Feb 2026Jallal BahijaCHIEF EXECUTIVE OFFICEROption exercise23,817
17 Feb 2026St Leger Tina AmberCHIEF HR OFFICEROption exercise2,119
05 Dec 2025Berman David MHEAD OF R&DOption exercise57210K USD
04 Dec 2025Berman David MHEAD OF R&DOption exercise31,341547K USD
28 Nov 2025Berman David MHEAD OF R&DOption exercise5,52196K USD
26 Nov 2025Berman David MHEAD OF R&DOption exercise69,4041.2M USD
25 Nov 2025Berman David MHEAD OF R&DOption exercise18,020315K USD
24 Nov 2025Berman David MHEAD OF R&DOption exercise1002K USD

Which funds hold Immunocore Holdings (IMCR)?

8 of the 45 institutional funds we track reported a Immunocore Holdings position for the quarter ended 30 Jun 2026 — a combined 188.5M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Immunocore Holdings (IMCR)?
FundPositionSharesValueShares q/q
Two Sigma InvestmentsAdded1,648,98352.4M USD+61.5%
Millennium ManagementAdded1,597,03750.7M USD+29.1%
Point72 Asset ManagementHeld (±25%)990,28031.4M USD−10.2%
Marshall WaceAdded590,94118.8M USD+227.7%
Citadel AdvisorsAdded566,76118.0M USD+146.0%
D. E. Shaw & Co.Held (±25%)405,11612.9M USD+20.9%
Renaissance TechnologiesTrimmed102,4003.3M USD−37.6%
Bridgewater AssociatesAdded36,7071.2M USD+93.9%
Baker Bros. AdvisorsExited
Balyasny Asset ManagementExited

What has been filed or recorded for Immunocore Holdings (IMCR)?

The filings we hold for Immunocore Holdings, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Immunocore Holdings (IMCR)?
And
14 Oct 2026Fails to deliverShares failed to deliver219 shares6K USD notional · <0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver296 shares9K USD notional · 0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.28 USD
30 Sep 2026FinancialsTotal assets1.1B USDat period end
30 Sep 2026FinancialsTotal equity419.7M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.02 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 0.25 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −0.71 USD
31 Dec 2025FinancialsRevenue400.0M USDfiscal year
31 Dec 2025FinancialsNet income−35.5M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−0.71 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 0.00 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.20 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 0.10 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.02 USD

Immunocore Holdings (IMCR): frequently asked questions

From live data
1.8B

What is Immunocore Holdings’ market cap?

Immunocore Holdings is worth 1.8B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

400.0M

What is Immunocore Holdings’ revenue?

Immunocore Holdings reported revenue of 400.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Immunocore Holdings insiders bought or sold shares recently?

No Immunocore Holdings insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 18 Feb 2026 (SEC Form 4). See Insiders

8 of 45

Which funds own Immunocore Holdings?

8 of the 45 funds we track reported a Immunocore Holdings position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Millennium Management and Point72 Asset Management. See Funds

−0.28

When did Immunocore Holdings last report earnings?

Immunocore Holdings last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.28 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings